Fisher Asset Management LLC Has $38 Million Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fisher Asset Management LLC raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 20.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 855,328 shares of the biopharmaceutical company’s stock after purchasing an additional 145,416 shares during the period. Fisher Asset Management LLC owned approximately 1.50% of Agios Pharmaceuticals worth $38,002,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AGIO. Caxton Associates LP lifted its holdings in shares of Agios Pharmaceuticals by 0.7% in the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after purchasing an additional 264 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Agios Pharmaceuticals by 1.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after acquiring an additional 540 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $37,000. Finally, Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $40,000.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $59.10 on Wednesday. The company has a market capitalization of $3.37 billion, a P/E ratio of 5.22 and a beta of 0.75. The business has a fifty day simple moving average of $47.66 and a two-hundred day simple moving average of $44.86. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on AGIO shares. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Friday, November 1st. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $52.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.